Search results for "PROGRESSION"

showing 10 items of 1251 documents

Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma

2016

Abstract Purpose : Neutrophilia is hallmark of classic Hodgkin Lymphoma (cHL), but its precise characterization remains elusive. We aimed at investigating the immunosuppressive role of high-density neutrophils in HL. Experimental design : First, N-HL function was evaluated in vitro, showing increased arginase (Arg-1) expression and activity compared to healthy subjects. Second, we measured serum level of Arg-1 (s-Arg-1) by ELISA in two independent, training (N=40) and validation (N=78) sets. Results : s-Arg-1 was higher in patients with advanced stage (p=0.045), B-symptoms (p=0.0048) and a positive FDG-PET scan after two cycles of chemotherapy (PET-2, p=0.012). Baseline levels of s-Arg-1 &g…

0301 basic medicineOncologymedicine.medical_specialtyPrognostic variableMyeloidmedicine.medical_treatmentImmunologyBiochemistry03 medical and health sciencesInternal medicinemedicineProgression-free survivalChemotherapybusiness.industryImmunosuppressionCell BiologyHematologymedicine.diseaseChemotherapy regimenNeutrophiliaLeukemia030104 developmental biologymedicine.anatomical_structureImmunologymedicine.symptombusinessBlood
researchProduct

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

2014

Abstract Background Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Field of study PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms “Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) “; papers considered relevant for the aim of this review were selected. Findings/results The phase I trials have determine…

0301 basic medicineOncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerTrastuzumabInternal medicineHumansMedicineMaytansineProgression-free survivalNeoplasm Metastasisskin and connective tissue diseasesTaxanebusiness.industryCancerHematologyTrastuzumabmedicine.diseaseMetastatic breast cancerClinical trial030104 developmental biologyClinical Trials Phase III as TopicOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisDisease ProgressionFemaleNeoplasm Recurrence Localbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis

2018

Abstract Introduction Carboplatin is the milestone of epithelial ovarian cancer (EOC) treatment, thus response to platinum is the major prognostic factor. Among platinum-sensitive patients, 40% carry a germline or somatic BRCA1/2 mutation. In this scenario a new class of drugs, the PARP inhibitors (PARPis), produced a significant improvement in long-term disease control. In order to make an aggregate evaluation of the impact of these agents, we performed a systematic review and meta-analysis. Patients and Methods Clinical trials were selected by searching “Pubmed” database and abstracts from major cancer meetings. We considered the January 2008 - April 2018 time frame. Progression free surv…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitorslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawOvarian cancerInternal medicinemedicineHumansMeta-analysiProgression-free survivalAdverse effectOvarian Neoplasmsbusiness.industryHazard ratioHematologyPrognosisClinical trial030104 developmental biologyPARP inhibitorOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCohortFemaleRandomized clinical trialMaintenance therapybusiness
researchProduct

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

2016

// Nicoletta Staropoli 1, * , Domenico Ciliberto 1, * , Silvia Chiellino 1 , Francesca Caglioti 1 , Teresa Del Giudice 1 , Simona Gualtieri 1 , Angela Salvino 1 , Alessandra Strangio 1 , Cirino Botta 1 , Sandro Pignata 2 , Pierfrancesco Tassone 1, * , Pierosandro Tagliaferri 1, * 1 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy 2 Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples, Naples, Italy * These authors have contributed equally to this work Correspondence to: Pierosandro Tagliaferri, email: tagliaferri@unicz.it Keywords: ovarian cancer, targeted therapy, systemic chemotherapy, systemat…

0301 basic medicineOncologymedicine.medical_specialtyTime FactorsBevacizumabmedicine.medical_treatmentAngiogenesis InhibitorsDisease-Free SurvivalTargeted therapyTargeted therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsOvarian cancerInternal medicineBiomarkers TumorOdds RatiomedicineHumansMeta-analysiMolecular Targeted TherapyPrecision MedicineSystemic chemotherapyOvarian Neoplasmsbusiness.industryPatient SelectionHazard ratioCancermedicine.diseaseCarboplatinmeta-analysisClinical trialTreatment Outcome030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisMeta-analysisDisease ProgressionSystematic reviewFemalePersonalized medicinebusinessResearch PaperSignal Transductionmedicine.drug
researchProduct

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin

2017

// Sergio Rizzo 1, * , Antonina Cangemi 1, * , Antonio Galvano 1, * , Daniele Fanale 1 , Silvio Buscemi 2 , Marcello Ciaccio 3 , Antonio Russo 1 , Sergio Castorina 4, 5, # and Viviana Bazan 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Department of Internal and Specialistic Medicine (DIBIMIS), Laboratory of Clinical Nutrition, University of Palermo, Palermo, Italy 3 Section of Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnology, University of Palermo, U.O.C. Laboratory Medicine, Policlinico University Hospital, Palermo, Italy 4 Fondazione Mediterranea…

0301 basic medicineOncologymedicine.medical_specialtychemotherapy responseClinical nutritiondoxorubicin03 medical and health sciences0302 clinical medicineInternal medicinemicroRNAmedicineDoxorubicinTriple-negative breast cancershort term starvationtriple negative breast cancer cellsbusiness.industryCancerMicroRNAmedicine.diseaseMolecular medicinemicroRNAstriple negative breast cancer cell030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisImmunologyBreast cancer cellsbusinessChemotherapy response; Doxorubicin; MicroRNAs; Short term starvation; triple negative breast cancer cells; Oncologymedicine.drugResearch PaperOncotarget
researchProduct

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer

2018

Giuseppe Cicero,1 Rossella De Luca,1 Francesco Dieli2 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, Palermo, Italy Background: In many clinical trials designed to assess the efficacy of anticancer treatments, overall survival (OS) is often used as a primary endpoint despite its several points of weakness. Methods: This study evaluated the role of progression-free survival (PFS) in the first three lines of treatment as a potential surrogate endpoint of OS in patients with metastatic colorectal cancer (MCRC). One hu…

0301 basic medicineOncologymedicine.medical_specialtycolorectal neoplasm overall survival progression-free survival surrogate endpoint liver metastates avastin egorafenibColorectal canceroverall survivalegorafenibOncoTargets and Therapy03 medical and health sciences0302 clinical medicineInternal medicinesurrogate endpoint liver metastatesOverall survivalClinical endpointMedicinePharmacology (medical)In patientProgression-free survivalavastinOriginal Researchbusiness.industryTime to progressionSurrogate endpointmedicine.diseaseClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesiscolorectal neoplasmbusinessprogression-free survivalOncoTargets and Therapy
researchProduct

A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis

2017

Background: The role of cortical lesions (CLs) in disease progression and clinical deficits is increasingly recognized in multiple sclerosis (MS); however the origin of CLs in MS still remains unclear. Objective: Here, we report a para-sulcal CL detected two years after diagnosis in a relapsing-remitting MS (RRMS) patient without manifestation of clinical deficit. Methods: Ultra-high field (7T) MR imaging using magnetization-prepared 2 rapid acquisition gradient echoes (MP2RAGE) sequence was performed. Results: A para-sulcal CL was detected which showed hypointense rim and iso- to hyperintense core. This was detected in the proximity of the leptomeninges in the left precentral gyrus extendi…

0301 basic medicinePathologymedicine.medical_specialty7TLesionMultiple sclerosis03 medical and health sciencesMeningeal inflammation0302 clinical medicineCLs upper limitsIn vivoatypical cortical lesionsmedicinemagnetic resonance imagingCORTICAL DEMYELINATIONmedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionMagnetic resonance imagingmedicine.disease030104 developmental biologyNeurologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Mice are not Men: ADAM30 Findings Emphasize a Broader Look Towards Murine Alzheimer's Disease Models

2016

Due to the growing population of people at advanced age, the number of patients affected by Alzheimer's disease (AD) is increasing tremendously. In 2015 about 46.8 million people suffered from AD worldwide which is estimated to increase to 131.5 million by 2050. Brains of AD patients all show a common histopathology; they are marked by an atrophy and degeneration that is caused by a severe loss of neurons and synapses (Braak and Del Tredici, 2012). Moreover, so-called extracellular senile plaques that consist of predominantly amyloid β (Aβ) peptides can be detected in the grey matter where they surround neurons. Since generation of Aβ peptides is hypothesized to play a major role in AD path…

0301 basic medicinePathologymedicine.medical_specialtyADAM10Populationlcsh:MedicineMice TransgenicGrey matterBiologyGeneral Biochemistry Genetics and Molecular BiologyPathogenesisMice03 medical and health sciences0302 clinical medicineAtrophyAlzheimer DiseasemedicineAmyloid precursor proteinAnimalsHumansSenile plaqueseducationlcsh:R5-920education.field_of_studylcsh:RP3 peptideGeneral Medicinemedicine.diseaseADAM ProteinsDisease Models Animal030104 developmental biologymedicine.anatomical_structureDisease ProgressionCommentarybiology.proteinlcsh:Medicine (General)Neuroscience030217 neurology & neurosurgeryEBioMedicine
researchProduct

Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis

2016

Background: Breakdown of extracellular matrix (ECM) is one of the important hallmarks of cancer progression which facilitates the invasion of tumoral cells to the surrounding tissue. Matrix metalloproteinases (MMPs) can degrade various components of the ECM and basement membrane. The aim of this study was to determine the role of matrix metalloproteinases-9 protein in the biologic behavior of oral squamous cell carcinoma (OSCC) and its relation with tumor angiogenesis. Material and Methods: In this study 42 OSCC and 15 normal epithelium were reviewed by immunohistochemical staining for matrix metalloproteinases-9 and CD105. Results: Matrix metalloproteinases-9 expression was detected in 32 …

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisOdontologíaMatrix metalloproteinaseMMP9Extracellular matrix03 medical and health sciences0302 clinical medicinemedicineGeneral DentistryBasement membraneOral Medicine and Pathologybusiness.industryResearchCancerEndoglin:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la salud030104 developmental biologymedicine.anatomical_structureTumor progression030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASbusinessJournal of Clinical and Experimental Dentistry
researchProduct

Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors

2016

// Irene Tadeo 1 , Gloria Bueno 2 , Ana P. Berbegall 1 , M. Milagro Fernandez-Carrobles 2 , Victoria Castel 3 , Marcial Garcia-Rojo 4 , Samuel Navarro 1 , Rosa Noguera 1 1 Pathology Department, Medical School, University of Valencia, INCLIVA, 46010 Valencia, Spain 2 VISILAB, E.T.S. Ingenieros Industriales, University of Castilla-La Mancha, 13071 Ciudad Real, Spain 3 Pediatric Oncology Unit, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain 4 Department of Pathology, Hospital de Jerez de la Frontera, 11407 Jerez de la Frontera, Cadiz, Spain Correspondence to: Rosa Noguera Salva, e-mail: rnoguera@uv.es Keywords: extracellular matrix, blood vessels, capillaries, sinusoids, neuro…

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisextracellular matrixMalignancyMetastasisblood vesselsNeuroblastoma03 medical and health sciencesneuroblastoma0302 clinical medicinePediatric oncologyMedicineHumansTumor growthcapillariesChildsinusoidsTissue microarrayNeovascularization Pathologicbusiness.industrymedicine.diseaseNeuroblastic Tumor030104 developmental biologyOncology030220 oncology & carcinogenesisCohortDisease ProgressionbusinessResearch Paper
researchProduct